References
- 1Bakker RA, Schoonus SB, Smit MJ, Timmerman H1, Leurs R. Histamine H1-receptor activation of nuclear factor-κB: roles for Gβγ- and Gαq/11-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol. 2001; 60:1133-42.BakkerRASchoonusSBSmitMJTimmermanHLeursRHistamine H1-receptor activation of nuclear factor-κB: roles for Gβγ- and Gαq/11-subunits in constitutive and agonist-mediated signalingMol Pharmacol200160113342
- 2Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002; 32:489-98.1197259210.1046/j.0954-7894.2002.01314.xLeursRChurchMKTaglialatelaMH1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effectsClin Exp Allergy20023248998
- 3Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011; 4:S22-7.10.1186/1939-4551-4-S3-S2223282332ChurchDSChurchMKPharmacology of antihistaminesWorld Allergy Organ J20114S227
- 4Gillard M, Benedetti MS, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res. 2005; 54:367-9.1627333410.1007/s00011-005-1368-3GillardMBenedettiMSChatelainPBaltesEHistamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistaminesInflamm Res2005543679
- 5Simons FER, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008; 1:145-55.23282578SimonsFERSimonsKJH1 antihistamines: current status and future directionsWorld Allergy Organ J2008114555
- 6Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005; 60:24-31.10.1111/j.1365-2125.2005.02377.xHorakFZieglmayerPUZieglmayerRKavinaALemellPLevocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administrationBr J Clin Pharmacol2005602431
- 7Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 (in collaboration with the World Health Organization, GA2LEN, and AllerGen). Allergy. 2008; 63:8-160.10.1111/j.1398-9995.2007.01620.xBousquetJKhaltaevNCruzAAet alAllergic rhinitis and its impact on asthma (ARIA) 2008 (in collaboration with the World Health Organization, GA2LEN, and AllerGen)Allergy2008638160
- 8Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet. 2008; 47:217-30.10.2165/00003088-200847040-0000118336052DevillierPRocheNFaisyCClinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative reviewClin Pharmacokinet20084721730
- 9Schoepke N, Church MK, Maurer M. The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. Acta Derm Venereol. 2013; 93:286-93.2314796410.2340/00015555-1490SchoepkeNChurchMKMaurerMThe inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteersActa Derm Venereol20139328693
- 10Dhanya NB, Thasleem Z, Rai R, Srinivas CR. Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression test. Indian J Dermatol Venereol Leprol. 2008; 74:361-3.1879705810.4103/0378-6323.42907DhanyaNBThasleemZRaiR inivas CR
Sr Comparative efficacy of levocetirizine, desloratidine and fexofenadine by histamine wheal suppression testIndian J Dermatol Venereol Leprol2008743613 - 11Kruszewski J, Klos K, Sulek K. [Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 i 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine—a randomized, double-blind; placebo controlled trial]. Pol Merkur Lekarski. 2006; 21:443-8. [in Polish]17345837KruszewskiJKlosKSulekK[Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 i 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine—a randomized, double-blind; placebo controlled trial]Pol Merkur Lekarski2006214438[in Polish]
- 12Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002; 88:190-7.1186892410.1016/S1081-1206(10)61995-3GrantJARiethuisenJMMoulaertBDeVosCA double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjectsAnn Allergy Asthma Immunol2002881907
- 13De Vos C, Mitchev K, Pinelli ME, Derde MP, Boev R. Non-interventional study comparing treatment satisfaction in patients treated with antihistamines. Clin Drug Investig. 2008; 28:221-30.1834571210.2165/00044011-200828040-00003De VosCMitchevKPinelliMEDerdeMPBoevRNon-interventional study comparing treatment satisfaction in patients treated with antihistaminesClin Drug Investig20082822130
- 14Bachert C. A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009; 31:921-44.1953909510.1016/j.clinthera.2009.05.017BachertCA review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitisClin Ther20093192144
- 15Lee DK, Gardiner M, Haggart K, Fujihara S, Lipworth BJ. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy. 2004; 34:650-3.10.1111/j.1365-2222.2004.1904.x15080821LeeDKGardinerMHaggartKFujiharaSLipworthBJComparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitisClin Exp Allergy2004346503
- 16Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004; 34:958-64.CiprandiGCirilloIVizzaccaroAToscaMALevocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitisa pilot studyClin Exp Allergy200434
- 17Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy. 2004; 34:1342-8.10.1111/j.1365-2222.2004.02026.x15347365AgrawalDKAnti-inflammatory properties of desloratadineClin Exp Allergy20043413428
- 18Schmidt J, Zalewski P, Olszewski J, Olszewska-Ziaber A. Histopathological verification of clinical indications to partial inferior turbinectomy. Rhinology. 2001; 39: 147-50.11721505SchmidtJZalewskiPOlszewskiJOlszewska-ZiaberAHistopathological verification of clinical indications to partial inferior turbinectomyRhinology20013914750
- 19Williams RG, Eccles R. Nasal airflow asymmetry and the effects of a topical nasal decongestant. Rhinology. 1992; 30:277-82.1281924WilliamsRGEcclesRNasal airflow asymmetry and the effects of a topical nasal decongestantRhinology19923027782
- 20Snidvongs K, Saengpanich S, Aeumjaturapat S, Phannaso C. Comparative study between the efficacy of local-made and original fexofenadine in persistent allergic rhinitis. Chula Med J. 2007; 51:289-302.SnidvongsKSaengpanichSAeumjaturapatSPhannasoCComparative study between the efficacy of local-made and original fexofenadine in persistent allergic rhinitisChula Med J200751289302